<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>21A. TUMOR IMMUNOLOGY</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-20c-vaccinology-2.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 66.67%;"></div> <!-- (26/39)*100 -->
                        </div>
                       <span class="progress-text">Lecture 26 of 39</span> 
                    </div>
                    <a href="immunology-21b-tumor-immunology-details.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">TUMOR IMMUNOLOGY.</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-teaching-objectives -->
                <section id="section-teaching-objectives" class="content-section" aria-labelledby="section-heading-teaching-objectives">
                    <h2 id="section-heading-teaching-objectives" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Teaching Objectives:</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Know the antigens expressed by cancer cells.</li>
                            <li>Understand the nature of immune response to tumors.</li>
                            <li>Study how cancers evade immune system.</li>
                            <li>Describe the approaches used in Immunotherapy.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-teaching-objectives -->

                <!-- START: section-tumor-immunology-intro -->
                <section id="section-tumor-immunology-intro" class="content-section" aria-labelledby="section-heading-tumor-immunology-intro">
                    <h2 id="section-heading-tumor-immunology-intro" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Tumor immunology</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Pathological cell masses derived by abnormal and uncontrollable clonal expansion of single cell.</li>
                            <li>Transformation of normal cells to malignant cells by:
                                <ol style="list-style-type: lower-alpha;">
                                    <li>Spontaneous mutation during daily cell division</li>
                                    <li>It may be induced by
                                        <ul>
                                            <li>chemical carcinogens</li>
                                            <li>physical carcinogens</li>
                                            <li>viruses</li>
                                        </ul>
                                    </li>
                                </ol>
                            </li>
                            <li>Cells become antigenically different from normal cells</li>
                            <li>They are recognized and destroyed by immune system</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-tumor-immunology-intro -->

                <!-- START: section-immune-surveillance-system -->
                <section id="section-immune-surveillance-system" class="content-section" aria-labelledby="section-heading-immune-surveillance-system">
                    <h2 id="section-heading-immune-surveillance-system" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Immune Surveillance System</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>During neoplastic transformation, new antigen develops</li>
                            <li>The host recognize them as non-self antigens</li>
                            <li>Cell mediated immune reactions attack these non-self tumor cells</li>
                            <li>Immune response act as surveillance system to detect and eliminate newly arising neoplastic cells</li>
                        </ul>
                        <p>This system include :</p>
                        <ol>
                            <li><strong>Natural killer (NK) cells</strong>
                                <ul><li>They kill directly tumor cells, helped by interferon, IL-2</li></ul>
                            </li>
                            <li><strong>Cytotoxic T-cells</strong>
                                <ul><li>They also kill directly tumor cells</li></ul>
                            </li>
                            <li><strong>Cell mediated T-cells (effector T-cells)</strong>
                                <ul><li>They produce and release a variety of lymphokines :
                                    <ol style="list-style-type: lower-alpha;">
                                        <li>Macrophage activation factor that activate macrophage</li>
                                        <li>Gamma interferon and interleukin-2 that activate NK</li>
                                        <li>Tumor necrosis factor (cachectine)</li>
                                    </ol>
                                </li></ul>
                            </li>
                            <li><strong>B-cells :</strong>
                                <ul>
                                    <li>Tumor associated antigens stimulate production of specific antibodies by host B-cells</li>
                                    <li>These specific antibodies bind together on tumor cell surface leading to destruction of tumor through:
                                        <ol style="list-style-type: lower-alpha;">
                                            <li>Antibody mediated-cytotoxicity :<br>
                                                Cytotoxic T-cells $\xrightarrow{\text{kill}}$ IgG-coated tumor cells</li>
                                            <li>Activation of macrophages<br>
                                                Sensitized T-cells $\xrightarrow{\text{release}}$ macrophage activating factor $\xrightarrow{\text{activates}}$ macrophages $\xrightarrow{\text{kill}}$ IgG-coated tumor cells</li>
                                            <li>Activation of classical pathway of complement leading to Lysis of tumor cells</li>
                                        </ol>
                                    </li>
                                </ul>
                            </li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-immune-surveillance-system -->

                <!-- START: section-tumor-escape -->
                <section id="section-tumor-escape" class="content-section" aria-labelledby="section-heading-tumor-escape">
                    <h2 id="section-heading-tumor-escape" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Tumor Escape</span>
                    </h2>
                    <div class="content-card">
                        <p>Mechanisms by which tumor escape immune defenses:</p>
                        <ol>
                            <li>Reduced levels or absence of MHCI molecule on tumor so that they can not be recognized by CTLs</li>
                            <li>Some tumors stop expressing the antigens
                                <ul><li>These tumors are called "antigen loss variants"</li></ul>
                            </li>
                            <li>Production of immunosuppressive factors by tumor e.g. transforming growth factor (TGF-$\beta$)</li>
                            <li>Tumor antigens may induce specific immunologic tolerance</li>
                            <li>Tumor cells have an inherent defect in antigen processing and presentation</li>
                            <li>Blocking of receptors on T-cells by specific antigen-antibodies complex (after shedding of tumor Ag) prevents them from recognizing and attacking tumor cells</li>
                            <li>Antigens on the surface of tumors may be masked by sialic acid-containing mucopolysaccharides</li>
                            <li>Immune suppression of the host as in transplant patients who show a higher incidence of malignancy</li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-tumor-escape -->

                <!-- START: section-tumor-markers -->
                <section id="section-tumor-markers" class="content-section" aria-labelledby="section-heading-tumor-markers">
                    <h2 id="section-heading-tumor-markers" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Tumor Markers</span>
                    </h2>
                    <div class="content-card">
                        <p>Tumor markers :</p>
                        <ul>
                            <li>They are either
                                <figure>
                                    <img src="../assets/images/2025_06_15_9acd2d1f0743a960ba14g-08-1.jpg" alt="Diagram illustrating that tumor markers can be tumor antigens or tumor products (enzymes, hormones) released into the serum." class="content-image">
                                </figure>
                            </li>
                            <li>Tumor products are released in the serum of patients</li>
                            <li>They are used to confirm diagnosis and follow up the response to therapy</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-tumor-markers -->

                <!-- START: section-tumor-antigens-markers -->
                <section id="section-tumor-antigens-markers" class="content-section" aria-labelledby="section-heading-tumor-antigens-markers">
                    <h2 id="section-heading-tumor-antigens-markers" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Tumor Antigens as tumor markers</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Alpha fetoprotein antigen (AFP) in cases of hepatoma</li>
                            <li>Carcinoembryoinic antigen (CEA) in gastrointestinal tumors, tumors of biliary system and cancer breast</li>
                            <li>Cancer antigen 125 (CA 125) in ovarian carcinoma</li>
                            <li>Cancer antigen 15-3 (CA15-3) in breast cancer</li>
                            <li>Cancer antigen 19-9 in colon and pancreatic tumor</li>
                            <li>Prostatic specific antigen (PSA) in prostatic tumors</li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-tumor-antigens-markers -->

                <!-- START: section-tumor-products-markers -->
                <section id="section-tumor-products-markers" class="content-section" aria-labelledby="section-heading-tumor-products-markers">
                    <h2 id="section-heading-tumor-products-markers" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Tumor Products (as markers)</span>
                    </h2>
                    <div class="content-card">
                        <ol style="list-style-type: lower-alpha;">
                            <li><strong>Hormones :</strong>
                                <ul>
                                    <li>Human chorionic gonadotrophins (HCG) are secreted in cases of choriocarcinoma</li>
                                    <li>Thyroxin (T3 & T4) is secreted in cases of cancer of thyroid gland</li>
                                </ul>
                            </li>
                            <li><strong>Enzymes :</strong>
                                <ul>
                                    <li>Acid phosphatase enzymes in cases of cancer of prostate</li>
                                    <li>Alkaline phosphatase, lipase and amylase enzymes in cases of cancer pancreas</li>
                                </ul>
                            </li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-tumor-products-markers -->

                <!-- START: section-immunotherapy -->
                <section id="section-immunotherapy" class="content-section" aria-labelledby="section-heading-immunotherapy">
                    <h2 id="section-heading-immunotherapy" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Immunotherapy.</span>
                    </h2>
                    <div class="content-card">
                        <p>Immunotherapy has been used as a novel mode to treat cancer.</p>
                        <p>Both active and passive means of stimulating the non-specific immune systems have been employed, in some cases with significant success.</p>
                        <ol>
                            <li><strong>Active Immunotherapy:</strong> Wherein the host actively participates in mounting an immune response
                                <ol style="list-style-type: lower-alpha;">
                                    <li><strong>Nonspecific:</strong>
                                        <ol style="list-style-type: lower-roman;">
                                            <li>Bacillus Calmette-Guerin (BCG)</li>
                                            <li>Corynebacterium parvum</li>
                                        </ol>
                                        <p>-These activate macrophages to be tumoricidal.</p>
                                    </li>
                                    <li><strong>Specific:</strong>
                                        <ol style="list-style-type: lower-roman;">
                                            <li>Hepatitis B vaccine</li>
                                            <li>Human Papilloma virus (HPV) vaccine</li>
                                        </ol>
                                    </li>
                                </ol>
                            </li>
                            <li><strong>Passive Immunotherapy:</strong> This involves transfer of preformed Abs, immune cells and other factors into the hosts.
                                <ol style="list-style-type: lower-alpha;">
                                    <li><strong>Specific:</strong>
                                        <ol style="list-style-type: lower-roman;">
                                            <li>Antibodies against tumor Ags (e.g. Her2/Neu for treatment of breast cancer)</li>
                                            <li>Abs against IL-2R for Human T lymphotropic virus (HTLV-1)induced adult T cell leukemia.</li>
                                            <li>Abs against CD20 expressed on non-Hodgkin's B cell lymphoma.</li>
                                            <li>Abs conjugated to toxins, radioisotopes and anti-cancer drugs have also been used. These enter the cells and inhibit protein synthesis. E.g. anti-CD20 conjugated to Pseudomonas toxin or ricin toxin.</li>
                                        </ol>
                                    </li>
                                    <li><strong>Nonspecific:</strong>
                                        <ol style="list-style-type: lower-roman;">
                                            <li>Adoptive Transfer of lymphocytes:
                                                <ol>
                                                    <li>Lymphokine-activated killer (LAK) cells which are IL2 activated T and NK cells.</li>
                                                    <li>Tumor-infiltrating lymphocytes (TIL)</li>
                                                </ol>
                                            </li>
                                            <li>Dendritic cells pulsed with tumor Ags may induce tumor-specific T cell responses. As tumor Ags are usually not known, tumor lysates are used.</li>
                                            <li>Cytokines
                                                <ol>
                                                    <li>IL-2: Activates T cells/NK cells used in the treatment of renal cell carcinoma and melanoma</li>
                                                    <li>Interferon alpha (IFN-$\alpha$): Induces MHC expression on tumors and used in the treatment of hairy B cell leukemias</li>
                                                    <li>Interferon gamma: Increases MHC expression; for treatment of ovarian cancers.</li>
                                                    <li>TNF-$\alpha$: Kills tumor cells.</li>
                                                </ol>
                                            </li>
                                            <li>Cytokine gene transfected tumor cells may also be used.</li>
                                        </ol>
                                    </li>
                                </ol>
                            </li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-immunotherapy -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-20c-vaccinology-2.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 66.67%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 26 of 39</span> 
                    </div>
                    <a href="immunology-21b-tumor-immunology-details.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>